Y Intercept Hong Kong Ltd Buys 26,325 Shares of Travere Therapeutics, Inc. $TVTX

Y Intercept Hong Kong Ltd grew its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 38.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 94,325 shares of the company’s stock after purchasing an additional 26,325 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Travere Therapeutics were worth $2,254,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. Emerald Mutual Fund Advisers Trust increased its position in shares of Travere Therapeutics by 5.2% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,200,942 shares of the company’s stock worth $28,703,000 after purchasing an additional 59,514 shares in the last quarter. Emerald Advisers LLC grew its stake in Travere Therapeutics by 2.6% during the third quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock worth $51,308,000 after buying an additional 55,407 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Travere Therapeutics by 67.7% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 213,918 shares of the company’s stock worth $5,113,000 after buying an additional 86,336 shares in the last quarter. Oak Ridge Investments LLC increased its holdings in shares of Travere Therapeutics by 32.5% during the third quarter. Oak Ridge Investments LLC now owns 68,232 shares of the company’s stock worth $1,631,000 after buying an additional 16,755 shares in the last quarter. Finally, Stephens Investment Management Group LLC bought a new position in shares of Travere Therapeutics in the third quarter valued at approximately $38,232,000.

Insider Buying and Selling

In other Travere Therapeutics news, insider William E. Rote sold 60,000 shares of Travere Therapeutics stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $40.10, for a total transaction of $2,406,000.00. Following the completion of the sale, the insider owned 101,443 shares of the company’s stock, valued at approximately $4,067,864.30. The trade was a 37.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christopher R. Cline sold 20,000 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $35.01, for a total value of $700,200.00. Following the completion of the transaction, the chief financial officer directly owned 92,083 shares in the company, valued at approximately $3,223,825.83. This trade represents a 17.84% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 270,564 shares of company stock worth $9,650,917. 4.06% of the stock is currently owned by company insiders.

Travere Therapeutics Trading Up 0.8%

Shares of TVTX opened at $30.28 on Thursday. The stock’s fifty day simple moving average is $34.35 and its 200-day simple moving average is $27.24. The firm has a market capitalization of $2.71 billion, a PE ratio of -28.57, a price-to-earnings-growth ratio of 0.99 and a beta of 0.85. Travere Therapeutics, Inc. has a 12-month low of $12.91 and a 12-month high of $42.13. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.59. The firm had revenue of $164.86 million during the quarter, compared to analyst estimates of $106.09 million. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The company’s revenue was up 162.1% on a year-over-year basis. During the same period last year, the company earned ($0.70) earnings per share. As a group, research analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TVTX shares. TD Cowen restated a “buy” rating on shares of Travere Therapeutics in a research report on Friday, October 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Guggenheim reissued a “buy” rating and issued a $49.00 price objective on shares of Travere Therapeutics in a research note on Wednesday, January 14th. Piper Sandler raised their target price on Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a report on Friday, November 28th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.86.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.